Alexander B. Olawaiye, MD

home / authors / alexander-b-olawaiye-md

Articles

Alexander B. Olawaiye, MD

Dr. Olawaiye on How to Address Disparities in Cancer Care

Alexander B. Olawaiye, MD
April 29th 2022

Alexander B. Olawaiye, MD, discusses how to address disparities in cancer care.

Read More

Alexander B. Olawaiye, MD,

Dr. Olawaiye on Front Line Treatment Sequencing Considerations in Ovarian Cancer

Alexander B. Olawaiye, MD
March 15th 2022

Alexander B. Olawaiye, MD, discusses front line treatment sequencing considerations in ovarian cancer.

Read More

Alexander B. Olawaiye, MD

Dr. Olawaiye on the Social and Biological Determinants of Disparities in Women’s Cancer

Alexander B. Olawaiye, MD
March 12th 2022

Alexander B. Olawaiye, MD, discusses the social and biological determinants of disparities in women’s cancer.

Read More

Alexander Babatunde Olawaiye, MD

Dr. Olawaiye on Investigating Balstilimab Plus Zalifrelimab in Gynecologic Cancers

Alexander B. Olawaiye, MD
February 1st 2022

Alexander Babatunde Olawaiye, MD, discusses the investigation of balstilimab plus zalifrelimab in gynecologic cancers.

Read More

Dr. Olawaiye on the Role of Surgery in Newly Diagnosed Ovarian Cancer

Dr. Olawaiye on the Role of Surgery in Newly Diagnosed Ovarian Cancer

Alexander B. Olawaiye, MD
April 3rd 2020

Alexander B. Olawaiye, MD, discusses the role of surgery in women with newly diagnosed ovarian cancer.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data